Search
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. … It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.
Categories: Selective T Cell Costimulation Blocker, T Lymphocyte Costimulation Activity BlockadeFludarabine
go.drugbank.com/drugs/DB01073ApprovedInvestigationalIt is commonly marketed under the brand name Fludara.
Products: Fludarabine Kabi 50mg Lyophilized Powder for Solution for Injection or InfusionDioxybenzone
go.drugbank.com/drugs/DB11221ApprovedWithdrawnIt absorbed UV-B and UV-AII rays. Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525].
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt was developed by The Medicines Company (acquired by Novartis). … It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
International brands: Ji Ni Le ErPropoxycaine
go.drugbank.com/drugs/DB09342ApprovedUsed in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592].
Iomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigational[A265090,A265095] Iomeprol first appeared in the market in 1994 [A265095] and is currently used in various diagnostic processes involving x-ray imaging and computed tomography (CT) scans.[L52260]
Aliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigational[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalIt works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]